Dr. Wu is a physician scientist with over two decades of oncology and global drug development expertise from previous corporate roles at CuraGen, Eisai, Legend, BMS, Novartis, and GSK. He was also trained as a molecular biologist with critical thinking and in-depth understanding of signaling mechanisms, cell cycle control, and molecular genetics. Dr. Wu upholds the values and importance of a robust team culture that enable a high-performance organization. At the industry-leading companies, Dr. Wu was responsible for scientific and strategic planning, collaborative management, and fast execution of multiple clinical programs with a successful track record in regulatory approvals of breakthrough therapies including small molecular inhibitors, monoclonal antibodies, and immunotherapeutics.

Dr. Wu received his PhD from University of Southern California, MS from University of Oregon and Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and his medical degree from Jiangxi Medical College of Nanchang University. Dr. Wu did his post-graduate training at Dana-Farber Cancer Institute, Harvard Medical School.